There are serious public health consequences related to the Tamoxifen Citrate case (Tamoxifen Citrate Antitrust Litigation, 429 F.3d 370 (2d Cir. 2005)), particularly for women’s health. The maneuvering to keep the Zeneca monopoly deprived women of generic competition for nearly a decade, a period when Tamoxifen was not only an important treatment modality for breast cancer, but also offered as a chemopreventive compound as well. If you are a full time legal academic and would like to read the draft amicus brief and consider signing on, contact Feminist Law Prof Eileen Kane: emk17 (at) dsl.psu.edu at your earliest convenience.
